Literature DB >> 23215798

A technique for systemic mesenchymal stem cell transplantation in newborn rat pups.

Jixin Yang1, Daniel Watkins, Chun-Liang Chen, Hong-Yi Zhang, Yu Zhou, Markus Velten, Gail E Besner.   

Abstract

Mesenchymal stem cells (MSC) have the potential to aid tissue regeneration. Intravenous (IV) MSC administration is currently being assessed following tissue injury. However, few studies have been performed to establish a safe and effective method of IV MSC infusion for newborns. We have established a safe, nontraumatic and effective technique for systemic MSC transplantation in newborn rats. Yellow-fluorescent-protein (YFP)-labeled MSC were characterized using MSC markers and their differentiation potential was confirmed. Rat pups were delivered by C-section on gestational day 21. The umbilical vein (UV) was cannulated and used for IV injection of MSC or saline control, which was performed under ultrasonographic imaging. An additional control group consisted of UV MSC injection in adult mice. Mean operating time, success rate of cannulation and death rate were recorded. YFP-MSC quantification in multiple organs was performed. Mean operating time was 3.9 ± 1.1 min. The success of UV MSC injection was 92.8%. The immediate and 24 hr delayed death rate for rat pups was significantly lower than that of adult mice (p < .05). No pups receiving saline injection died. After locating the patent foramen ovale (PFO) of newborn pups by ultrasonographic imaging, extra pulse-waves and wave-shape changes were detected when MSC were injected. The number of YFP-MSC was 15.8 ± 4.1 cells per visual field (CPVF) in the lungs, 2.9 ± 1.2 CPVF in the heart, and 19.8 ± 5.0 CPVF in the intestines. We conclude that IV MSC infusion through the UV is a convenient, safe, and effective method for systemic MSC transplantation in prematurely delivered newborn rats.

Entities:  

Mesh:

Year:  2012        PMID: 23215798     DOI: 10.3109/08941939.2012.661519

Source DB:  PubMed          Journal:  J Invest Surg        ISSN: 0894-1939            Impact factor:   2.533


  7 in total

1.  Heparin-binding epidermal growth factor-like growth factor and mesenchymal stem cells act synergistically to prevent experimental necrotizing enterocolitis.

Authors:  Jixin Yang; Daniel Watkins; Chun-Liang Chen; Bharath Bhushan; Yu Zhou; Gail E Besner
Journal:  J Am Coll Surg       Date:  2012-07-21       Impact factor: 6.113

2.  Evaluating the efficacy of different types of stem cells in preserving gut barrier function in necrotizing enterocolitis.

Authors:  Christopher J McCulloh; Jacob K Olson; Yijie Wang; Jennifer Vu; Sarah Gartner; Gail E Besner
Journal:  J Surg Res       Date:  2017-03-31       Impact factor: 2.192

3.  Stem cells and necrotizing enterocolitis: A direct comparison of the efficacy of multiple types of stem cells.

Authors:  Christopher J McCulloh; Jacob K Olson; Yu Zhou; Yijie Wang; Gail E Besner
Journal:  J Pediatr Surg       Date:  2017-03-18       Impact factor: 2.545

4.  Treatment of experimental necrotizing enterocolitis with stem cell-derived exosomes.

Authors:  Christopher J McCulloh; Jacob K Olson; Yijie Wang; Yu Zhou; Natalie Huibregtse Tengberg; Shivani Deshpande; Gail E Besner
Journal:  J Pediatr Surg       Date:  2018-03-14       Impact factor: 2.545

5.  Heparin-binding EGF-like growth factor (HB-EGF) therapy for intestinal injury: Application and future prospects.

Authors:  Jixin Yang; Yanwei Su; Yu Zhou; Gail E Besner
Journal:  Pathophysiology       Date:  2013-12-15

Review 6.  Stem cell therapy as a promising strategy in necrotizing enterocolitis.

Authors:  Si-Jia Di; Si-Yuan Wu; Tian-Jing Liu; Yong-Yan Shi
Journal:  Mol Med       Date:  2022-09-06       Impact factor: 6.376

7.  Human placental-derived stem cell therapy ameliorates experimental necrotizing enterocolitis.

Authors:  Victoria G Weis; Anna C Deal; Gehad Mekkey; Cara Clouse; Michaela Gaffley; Emily Whitaker; Cole B Peeler; Jared A Weis; Marshall Z Schwartz; Anthony Atala
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2021-02-10       Impact factor: 4.052

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.